Celcuity Inc. (CELC) 10-Year Financial Performance & Capital Metrics

CELC •

HealthcareBiotechnologyOncology Therapeutics Developers

AboutCelcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.Show more

Revenue $0
EBITDA -$113M -71.2%
Net Income -$112M -75.3%
EPS (Diluted) -2.83 -5.2%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -87.54% -87.7%
ROIC -50.32% -47.4%
Debt/Equity 0.85 +216.2%
Interest Coverage -11.02 +11.4%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 98 (top 2%)

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Shares diluted 66.6% in last year
✗Expensive at 38.1x book value
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-73.16%

EPS CAGR

10Y-

5Y-

3Y-

TTM-40.61%

ROCE

10Y Avg-45.13%

5Y Avg-49.7%

3Y Avg-42.52%

Latest-58.02%

Peer Comparison

Oncology Therapeutics Developers

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
EXELExelixis, Inc.	11.81B	44.06	15.85	6.98%	29.63%	31.37%	7.49%	0.08
INCYIncyte Corporation	20.1B	101.27	15.80	21.22%	25.03%	24.9%	6.74%	0.01
GMABGenmab A/S	18.13B	29.44	15.36	30.67%	46.8%	114.25%	6.6%	0.03
SNDXSyndax Pharmaceuticals, Inc.	1.89B	21.71	-5.82		-279.31%	-269.93%		1.20
RCUSArcus Biosciences, Inc.	2.55B	20.37	-6.19	-4.26%	-142.91%	-55.94%		0.16
RLAYRelay Therapeutics, Inc.	1.78B	10.26	-6.37	53.44%	-18.01%	-48.76%		0.06
STROSutro Biopharma, Inc.	1.74B	20.47	-6.92	-59.64%	-205.18%	-234.19%		4.57
OLMAOlema Pharmaceuticals, Inc.	1.66B	24.20	-11			-48.77%		0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	58.38K	73.06K	104.7K	223.04K	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-58.38K	-73.06K	-104.7K	-223.04K	0	0	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-25.15%	-43.31%	-113.02%	100%	-	-	-	-	-
Operating Expenses+	2.26M	3.33M	5.95M	7.93M	7.81M	9.56M	28.36M	39.39M	66.23M	113.27M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	250.09K	263.66K	972.52K	1.61M	1.78M	2.13M	2.6M	4.38M	5.64M	9.06M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	2.01M	3.06M	4.98M	6.33M	6.27M	7.68M	25.76M	35.29M	60.59M	104.2M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	-247.14K	-256.8K	0	-278.84K	0	0
Operating Income+	-2.26M	-3.33M	-5.95M	-7.93M	-7.81M	-9.56M	-28.36M	-39.39M	-66.23M	-113.27M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-	-47.16%	-78.85%	-33.25%	1.6%	-22.43%	-196.73%	-38.92%	-68.14%	-71.02%
EBITDA+	-2.2M	-3.26M	-5.85M	-7.71M	-7.47M	-9.17M	-28.05M	-39.18M	-66.09M	-113.14M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-	-47.74%	-79.65%	-31.83%	3.15%	-22.83%	-205.9%	-39.67%	-68.68%	-71.19%
D&A (Non-Cash Add-back)	58.38K	73.06K	104.7K	223.04K	339K	385.59K	303.24K	210.92K	142.77K	129.95K
EBIT	-2.26M	-3.33M	-5.95M	-7.48M	-7.81M	-9.56M	-28.34M	-39.39M	-58.45M	-101.5M
Net Interest Income+	0	0	-298.79K	448.72K	445.94K	81.99K	-1.25M	-978.95K	2.45M	1.49M
Interest Income	268	18.02K	152.88K	448.83K	446.1K	82.11K	13.26K	1.13M	7.78M	11.77M
Interest Expense	0	0	451.66K	111	159	120	1.26M	2.11M	5.33M	10.28M
Other Income/Expense	268	18.02K	-298.79K	451.72K	445.94K	81.99K	-1.25M	-978.95K	2.45M	1.49M
Pretax Income+	-2.26M	-3.31M	-6.25M	-7.48M	-7.36M	-9.47M	-29.61M	-40.37M	-63.78M	-111.78M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	0	0	48.17K	0	0	0	0	0	0	0
Effective Tax Rate %	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%
Net Income+	-2.26M	-3.31M	-6.25M	-7.48M	-7.36M	-9.47M	-29.61M	-40.37M	-63.78M	-111.78M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-	-46.38%	-88.85%	-19.66%	1.62%	-28.74%	-212.48%	-36.36%	-57.99%	-75.26%
Net Income (Continuing)	-2.26M	-3.31M	-6.25M	-7.48M	-7.36M	-9.47M	-29.61M	-40.37M	-63.78M	-111.78M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.36	-0.49	-0.84	-0.74	-0.69	-0.89	-2.28	-2.68	-2.69	-2.83
EPS Growth %	-	-36.11%	-71.43%	11.9%	6.76%	-28.99%	-156.18%	-17.54%	-0.37%	-5.2%
EPS (Basic)	-0.36	-0.49	-0.84	-0.74	-0.69	-0.89	-2.28	-2.68	-2.69	-2.83
Diluted Shares Outstanding	6.31M	6.72M	7.46M	10.12M	10.23M	10.27M	13.38M	15.42M	23.68M	39.45M
Basic Shares Outstanding	6.31M	6.72M	7.46M	10.12M	10.23M	10.27M	13.38M	15.42M	23.68M	39.45M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	5.12M	5.91M	24.48M	25.22M	19.25M	12.17M	85.35M	175.16M	190.59M	244.57M
Cash & Short-Term Investments	5.07M	5.86M	24.2M	24.9M	18.76M	11.66M	84.29M	168.59M	180.58M	235.1M
Cash Only	5.07M	5.86M	2.64M	15.94M	18.74M	11.64M	84.29M	24.57M	30.66M	22.51M
Short-Term Investments	0	0	21.56M	8.95M	22.01K	22.01K	0	144.02M	149.92M	212.59M
Accounts Receivable	0	0	0	0	0	0	298.76K	203.66K	805.88K	1.6M
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	55.72K	50K	50K	28.74K	218.74K	190K	22.14K	22.01K	281.36K	841.33K
Total Non-Current Assets+	177.07K	144.91K	7.49M	813.61K	1.03M	789.79K	554.35K	539.75K	628.8K	552.02K
Property, Plant & Equipment	177.07K	144.91K	280.06K	813.61K	1.03M	789.79K	554.35K	506.56K	628.8K	552.02K
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	7.21M	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	0	0	0	0	0	33.2K	0	0
Total Assets+	5.3M	6.06M	31.97M	26.03M	20.28M	12.96M	85.91M	175.7M	191.22M	245.12M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	-	14.28%	427.81%	-18.57%	-22.09%	-36.11%	563.02%	104.52%	8.83%	28.19%
Total Current Liabilities+	283.6K	445.36K	578.05K	662.33K	911.33K	1.19M	2.51M	6.88M	14.19M	31.72M
Accounts Payable	261.75K	331.53K	71.91K	119.81K	142.77K	217.38K	1.51M	2.63M	5.08M	9.37M
Days Payables Outstanding	1.64K	1.66K	250.69	196.07	-	-	-	-	-	-
Short-Term Debt	0	0	0	0	0	0	0	194.2K	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	0	0	54.51K	63.88K	0	0	472.93K	3.09M	7.11M	0
Current Ratio	18.06x	13.27x	42.36x	38.07x	21.12x	10.26x	34.06x	25.45x	13.43x	7.71x
Quick Ratio	18.06x	13.27x	42.36x	38.07x	21.12x	10.26x	34.06x	25.45x	13.43x	7.71x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	0	19.88K	71.9K	69.16K	14.69M	35.04M	37.26M	97.78M
Long-Term Debt	0	0	0	0	0	0	14.63M	34.98M	37.04M	97.73M
Capital Lease Obligations	0	0	0	19.88K	71.9K	69.16K	64.22K	61K	225.92K	53.97K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0	0	0
Total Liabilities	283.6K	445.36K	578.05K	682.21K	983.23K	1.25M	17.2M	41.93M	51.45M	129.5M
Total Debt+	0	0	0	25.61K	256.14K	262.49K	14.89M	35.24M	37.45M	97.95M
Net Debt	-5.07M	-5.86M	-2.64M	-15.92M	-18.48M	-11.38M	-69.4M	10.67M	6.78M	75.44M
Debt / Equity	-	-	-	0.00x	0.01x	0.02x	0.22x	0.26x	0.27x	0.85x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-13.18x	-71464.31x	-49089.94x	-79634.70x	-22.46x	-18.70x	-12.43x	-11.02x
Total Equity+	5.02M	5.61M	31.39M	25.35M	19.3M	11.7M	68.71M	133.77M	139.77M	115.62M
Equity Growth %	-	11.87%	459.4%	-19.25%	-23.87%	-39.36%	487.16%	94.69%	4.48%	-17.28%
Book Value per Share	0.79	0.84	4.21	2.50	1.89	1.14	5.13	8.68	5.90	2.93
Total Shareholders' Equity	5.02M	5.61M	31.39M	25.35M	19.3M	11.7M	68.71M	133.77M	139.77M	115.62M
Common Stock	5.89K	6.44K	10.09K	10.19K	10.25K	10.3K	14.92K	21.67K	25.51K	37.14K
Retained Earnings	-5.02M	-8.33M	-2.01M	-9.49M	-16.85M	-26.32M	-55.93M	-96.3M	-160.08M	-271.86M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-82.36K	-155.41K	-260.12K	-480.9K	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-1.98M	-2.89M	-4.95M	-6.08M	-6M	-7.15M	-20.31M	-36.01M	-53.81M	-83.47M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-	-45.96%	-71.31%	-22.8%	1.28%	-19.12%	-184.25%	-77.28%	-49.44%	-55.11%
Net Income	-2.26M	-3.31M	-6.25M	-7.48M	-7.36M	-9.47M	-29.61M	-40.37M	-63.78M	-111.78M
Depreciation & Amortization	58.38K	73.06K	104.7K	223.04K	339K	385.59K	303.24K	210.92K	142.77K	129.95K
Stock-Based Compensation	56.51K	187.31K	874.39K	1.17M	1.04M	1.76M	2.61M	4.64M	4.9M	6.99M
Deferred Taxes	-56.51K	-187.31K	0	-92.32K	0	-2.48M	0	0	0	0
Other Non-Cash Items	56.51K	187.31K	426.57K	89.32K	42.91K	2.48M	5.56M	704.66K	1.06M	2.84M
Working Capital Changes	167.88K	161.75K	-101.91K	15.89K	-62.24K	179.02K	819.81K	-1.19M	3.86M	18.35M
Change in Receivables	0	0	0	0	-190K	0	-108.76K	95.1K	0	0
Change in Inventory	0	0	0	0	190K	0	0	0	0	0
Change in Payables	157.47K	69.78K	-262.51K	25.43K	45.62K	52.97K	1.31M	1.08M	2.43M	4.32M
Cash from Investing+	-78.98K	-40.9K	-28.98M	19.09M	8.53M	-89.37K	-81.4K	-144.03M	-5.01M	-63.07M
Capital Expenditures	-78.98K	-40.9K	-239.85K	-629.61K	-380.2K	-89.37K	-81.9K	-158.77K	-97.64K	-249.88K
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	0	0	0	4K	0	0	0	0	0	0
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	-28.74M	4K	8.91K	0	500	0	0	0
Cash from Financing+	4.8M	3.72M	30.71M	236.7K	259.31K	137.97K	93.04M	120.33M	64.91M	138.39M
Debt Issued (Net)	0	0	7.49M	-3.32K	-5.73K	-5.77K	14.34M	19.5M	-2.45K	59.23M
Equity Issued (Net)	1000K	1000K	1000K	0	0	182.69K	1000K	1000K	1000K	1000K
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	0	0	0	-55.14K	0	0	0	0	0	0
Other Financing	1M	0	-894.57K	240.02K	265.04K	-38.96K	148.02K	324.12K	50.48M	15.55M
Net Change in Cash	2.74M	789.11K	-3.22M	13.25M	2.79M	-7.1M	72.65M	-59.71M	6.09M	-8.15M
Free Cash Flow+	-2.06M	-2.93M	-5.19M	-6.71M	-6.38M	-7.24M	-20.39M	-36.17M	-53.91M	-83.72M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-	-42.35%	-77.11%	-29.26%	4.88%	-13.42%	-181.88%	-77.34%	-49.06%	-55.29%
FCF per Share	-0.33	-0.44	-0.70	-0.66	-0.62	-0.70	-1.52	-2.35	-2.28	-2.12
FCF Conversion (FCF/Net Income)	0.87x	0.87x	0.79x	0.81x	0.82x	0.75x	0.69x	0.89x	0.84x	0.75x
Interest Paid	0	0	0	0	0	0	694.53K	1.26M	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-45.08%	-62.3%	-33.79%	-26.37%	-32.97%	-61.12%	-73.63%	-39.88%	-46.63%	-87.54%
Return on Invested Capital (ROIC)	-	-	-31.32%	-31.16%	-114.23%	-1251.29%	-	-41.1%	-34.14%	-50.32%
Debt / Equity	-	-	-	0.00x	0.01x	0.02x	0.22x	0.26x	0.27x	0.85x
Interest Coverage	-	-	-13.18x	-71464.31x	-49089.94x	-79634.70x	-22.46x	-18.70x	-12.43x	-11.02x
FCF Conversion	0.87x	0.87x	0.79x	0.81x	0.82x	0.75x	0.69x	0.89x	0.84x	0.75x

US Stock Screener

...

Celcuity Inc. (CELC) 10-Year Financial Performance & Capital Metrics

CELC •

HealthcareBiotechnologyOncology Therapeutics Developers

Revenue $0
EBITDA -$113M -71.2%
Net Income -$112M -75.3%
EPS (Diluted) -2.83 -5.2%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -87.54% -87.7%
ROIC -50.32% -47.4%
Debt/Equity 0.85 +216.2%
Interest Coverage -11.02 +11.4%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 98 (top 2%)

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Shares diluted 66.6% in last year
✗Expensive at 38.1x book value
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-73.16%

EPS CAGR

10Y-

5Y-

3Y-

TTM-40.61%

ROCE

10Y Avg-45.13%

5Y Avg-49.7%

3Y Avg-42.52%

Latest-58.02%

Peer Comparison

Oncology Therapeutics Developers

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
EXELExelixis, Inc.	11.81B	44.06	15.85	6.98%	29.63%	31.37%	7.49%	0.08
INCYIncyte Corporation	20.1B	101.27	15.80	21.22%	25.03%	24.9%	6.74%	0.01
GMABGenmab A/S	18.13B	29.44	15.36	30.67%	46.8%	114.25%	6.6%	0.03
SNDXSyndax Pharmaceuticals, Inc.	1.89B	21.71	-5.82		-279.31%	-269.93%		1.20
RCUSArcus Biosciences, Inc.	2.55B	20.37	-6.19	-4.26%	-142.91%	-55.94%		0.16
RLAYRelay Therapeutics, Inc.	1.78B	10.26	-6.37	53.44%	-18.01%	-48.76%		0.06
STROSutro Biopharma, Inc.	1.74B	20.47	-6.92	-59.64%	-205.18%	-234.19%		4.57
OLMAOlema Pharmaceuticals, Inc.	1.66B	24.20	-11			-48.77%		0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	58.38K	73.06K	104.7K	223.04K	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-58.38K	-73.06K	-104.7K	-223.04K	0	0	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-25.15%	-43.31%	-113.02%	100%	-	-	-	-	-
Operating Expenses+	2.26M	3.33M	5.95M	7.93M	7.81M	9.56M	28.36M	39.39M	66.23M	113.27M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	250.09K	263.66K	972.52K	1.61M	1.78M	2.13M	2.6M	4.38M	5.64M	9.06M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	2.01M	3.06M	4.98M	6.33M	6.27M	7.68M	25.76M	35.29M	60.59M	104.2M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	-247.14K	-256.8K	0	-278.84K	0	0
Operating Income+	-2.26M	-3.33M	-5.95M	-7.93M	-7.81M	-9.56M	-28.36M	-39.39M	-66.23M	-113.27M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-	-47.16%	-78.85%	-33.25%	1.6%	-22.43%	-196.73%	-38.92%	-68.14%	-71.02%
EBITDA+	-2.2M	-3.26M	-5.85M	-7.71M	-7.47M	-9.17M	-28.05M	-39.18M	-66.09M	-113.14M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-	-47.74%	-79.65%	-31.83%	3.15%	-22.83%	-205.9%	-39.67%	-68.68%	-71.19%
D&A (Non-Cash Add-back)	58.38K	73.06K	104.7K	223.04K	339K	385.59K	303.24K	210.92K	142.77K	129.95K
EBIT	-2.26M	-3.33M	-5.95M	-7.48M	-7.81M	-9.56M	-28.34M	-39.39M	-58.45M	-101.5M
Net Interest Income+	0	0	-298.79K	448.72K	445.94K	81.99K	-1.25M	-978.95K	2.45M	1.49M
Interest Income	268	18.02K	152.88K	448.83K	446.1K	82.11K	13.26K	1.13M	7.78M	11.77M
Interest Expense	0	0	451.66K	111	159	120	1.26M	2.11M	5.33M	10.28M
Other Income/Expense	268	18.02K	-298.79K	451.72K	445.94K	81.99K	-1.25M	-978.95K	2.45M	1.49M
Pretax Income+	-2.26M	-3.31M	-6.25M	-7.48M	-7.36M	-9.47M	-29.61M	-40.37M	-63.78M	-111.78M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	0	0	48.17K	0	0	0	0	0	0	0
Effective Tax Rate %	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%
Net Income+	-2.26M	-3.31M	-6.25M	-7.48M	-7.36M	-9.47M	-29.61M	-40.37M	-63.78M	-111.78M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-	-46.38%	-88.85%	-19.66%	1.62%	-28.74%	-212.48%	-36.36%	-57.99%	-75.26%
Net Income (Continuing)	-2.26M	-3.31M	-6.25M	-7.48M	-7.36M	-9.47M	-29.61M	-40.37M	-63.78M	-111.78M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.36	-0.49	-0.84	-0.74	-0.69	-0.89	-2.28	-2.68	-2.69	-2.83
EPS Growth %	-	-36.11%	-71.43%	11.9%	6.76%	-28.99%	-156.18%	-17.54%	-0.37%	-5.2%
EPS (Basic)	-0.36	-0.49	-0.84	-0.74	-0.69	-0.89	-2.28	-2.68	-2.69	-2.83
Diluted Shares Outstanding	6.31M	6.72M	7.46M	10.12M	10.23M	10.27M	13.38M	15.42M	23.68M	39.45M
Basic Shares Outstanding	6.31M	6.72M	7.46M	10.12M	10.23M	10.27M	13.38M	15.42M	23.68M	39.45M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	5.12M	5.91M	24.48M	25.22M	19.25M	12.17M	85.35M	175.16M	190.59M	244.57M
Cash & Short-Term Investments	5.07M	5.86M	24.2M	24.9M	18.76M	11.66M	84.29M	168.59M	180.58M	235.1M
Cash Only	5.07M	5.86M	2.64M	15.94M	18.74M	11.64M	84.29M	24.57M	30.66M	22.51M
Short-Term Investments	0	0	21.56M	8.95M	22.01K	22.01K	0	144.02M	149.92M	212.59M
Accounts Receivable	0	0	0	0	0	0	298.76K	203.66K	805.88K	1.6M
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	55.72K	50K	50K	28.74K	218.74K	190K	22.14K	22.01K	281.36K	841.33K
Total Non-Current Assets+	177.07K	144.91K	7.49M	813.61K	1.03M	789.79K	554.35K	539.75K	628.8K	552.02K
Property, Plant & Equipment	177.07K	144.91K	280.06K	813.61K	1.03M	789.79K	554.35K	506.56K	628.8K	552.02K
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	7.21M	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	0	0	0	0	0	33.2K	0	0
Total Assets+	5.3M	6.06M	31.97M	26.03M	20.28M	12.96M	85.91M	175.7M	191.22M	245.12M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	-	14.28%	427.81%	-18.57%	-22.09%	-36.11%	563.02%	104.52%	8.83%	28.19%
Total Current Liabilities+	283.6K	445.36K	578.05K	662.33K	911.33K	1.19M	2.51M	6.88M	14.19M	31.72M
Accounts Payable	261.75K	331.53K	71.91K	119.81K	142.77K	217.38K	1.51M	2.63M	5.08M	9.37M
Days Payables Outstanding	1.64K	1.66K	250.69	196.07	-	-	-	-	-	-
Short-Term Debt	0	0	0	0	0	0	0	194.2K	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	0	0	54.51K	63.88K	0	0	472.93K	3.09M	7.11M	0
Current Ratio	18.06x	13.27x	42.36x	38.07x	21.12x	10.26x	34.06x	25.45x	13.43x	7.71x
Quick Ratio	18.06x	13.27x	42.36x	38.07x	21.12x	10.26x	34.06x	25.45x	13.43x	7.71x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	0	19.88K	71.9K	69.16K	14.69M	35.04M	37.26M	97.78M
Long-Term Debt	0	0	0	0	0	0	14.63M	34.98M	37.04M	97.73M
Capital Lease Obligations	0	0	0	19.88K	71.9K	69.16K	64.22K	61K	225.92K	53.97K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0	0	0
Total Liabilities	283.6K	445.36K	578.05K	682.21K	983.23K	1.25M	17.2M	41.93M	51.45M	129.5M
Total Debt+	0	0	0	25.61K	256.14K	262.49K	14.89M	35.24M	37.45M	97.95M
Net Debt	-5.07M	-5.86M	-2.64M	-15.92M	-18.48M	-11.38M	-69.4M	10.67M	6.78M	75.44M
Debt / Equity	-	-	-	0.00x	0.01x	0.02x	0.22x	0.26x	0.27x	0.85x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-13.18x	-71464.31x	-49089.94x	-79634.70x	-22.46x	-18.70x	-12.43x	-11.02x
Total Equity+	5.02M	5.61M	31.39M	25.35M	19.3M	11.7M	68.71M	133.77M	139.77M	115.62M
Equity Growth %	-	11.87%	459.4%	-19.25%	-23.87%	-39.36%	487.16%	94.69%	4.48%	-17.28%
Book Value per Share	0.79	0.84	4.21	2.50	1.89	1.14	5.13	8.68	5.90	2.93
Total Shareholders' Equity	5.02M	5.61M	31.39M	25.35M	19.3M	11.7M	68.71M	133.77M	139.77M	115.62M
Common Stock	5.89K	6.44K	10.09K	10.19K	10.25K	10.3K	14.92K	21.67K	25.51K	37.14K
Retained Earnings	-5.02M	-8.33M	-2.01M	-9.49M	-16.85M	-26.32M	-55.93M	-96.3M	-160.08M	-271.86M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-82.36K	-155.41K	-260.12K	-480.9K	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-1.98M	-2.89M	-4.95M	-6.08M	-6M	-7.15M	-20.31M	-36.01M	-53.81M	-83.47M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-	-45.96%	-71.31%	-22.8%	1.28%	-19.12%	-184.25%	-77.28%	-49.44%	-55.11%
Net Income	-2.26M	-3.31M	-6.25M	-7.48M	-7.36M	-9.47M	-29.61M	-40.37M	-63.78M	-111.78M
Depreciation & Amortization	58.38K	73.06K	104.7K	223.04K	339K	385.59K	303.24K	210.92K	142.77K	129.95K
Stock-Based Compensation	56.51K	187.31K	874.39K	1.17M	1.04M	1.76M	2.61M	4.64M	4.9M	6.99M
Deferred Taxes	-56.51K	-187.31K	0	-92.32K	0	-2.48M	0	0	0	0
Other Non-Cash Items	56.51K	187.31K	426.57K	89.32K	42.91K	2.48M	5.56M	704.66K	1.06M	2.84M
Working Capital Changes	167.88K	161.75K	-101.91K	15.89K	-62.24K	179.02K	819.81K	-1.19M	3.86M	18.35M
Change in Receivables	0	0	0	0	-190K	0	-108.76K	95.1K	0	0
Change in Inventory	0	0	0	0	190K	0	0	0	0	0
Change in Payables	157.47K	69.78K	-262.51K	25.43K	45.62K	52.97K	1.31M	1.08M	2.43M	4.32M
Cash from Investing+	-78.98K	-40.9K	-28.98M	19.09M	8.53M	-89.37K	-81.4K	-144.03M	-5.01M	-63.07M
Capital Expenditures	-78.98K	-40.9K	-239.85K	-629.61K	-380.2K	-89.37K	-81.9K	-158.77K	-97.64K	-249.88K
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	0	0	0	4K	0	0	0	0	0	0
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	-28.74M	4K	8.91K	0	500	0	0	0
Cash from Financing+	4.8M	3.72M	30.71M	236.7K	259.31K	137.97K	93.04M	120.33M	64.91M	138.39M
Debt Issued (Net)	0	0	7.49M	-3.32K	-5.73K	-5.77K	14.34M	19.5M	-2.45K	59.23M
Equity Issued (Net)	1000K	1000K	1000K	0	0	182.69K	1000K	1000K	1000K	1000K
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	0	0	0	-55.14K	0	0	0	0	0	0
Other Financing	1M	0	-894.57K	240.02K	265.04K	-38.96K	148.02K	324.12K	50.48M	15.55M
Net Change in Cash	2.74M	789.11K	-3.22M	13.25M	2.79M	-7.1M	72.65M	-59.71M	6.09M	-8.15M
Free Cash Flow+	-2.06M	-2.93M	-5.19M	-6.71M	-6.38M	-7.24M	-20.39M	-36.17M	-53.91M	-83.72M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-	-42.35%	-77.11%	-29.26%	4.88%	-13.42%	-181.88%	-77.34%	-49.06%	-55.29%
FCF per Share	-0.33	-0.44	-0.70	-0.66	-0.62	-0.70	-1.52	-2.35	-2.28	-2.12
FCF Conversion (FCF/Net Income)	0.87x	0.87x	0.79x	0.81x	0.82x	0.75x	0.69x	0.89x	0.84x	0.75x
Interest Paid	0	0	0	0	0	0	694.53K	1.26M	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-45.08%	-62.3%	-33.79%	-26.37%	-32.97%	-61.12%	-73.63%	-39.88%	-46.63%	-87.54%
Return on Invested Capital (ROIC)	-	-	-31.32%	-31.16%	-114.23%	-1251.29%	-	-41.1%	-34.14%	-50.32%
Debt / Equity	-	-	-	0.00x	0.01x	0.02x	0.22x	0.26x	0.27x	0.85x
Interest Coverage	-	-	-13.18x	-71464.31x	-49089.94x	-79634.70x	-22.46x	-18.70x	-12.43x	-11.02x
FCF Conversion	0.87x	0.87x	0.79x	0.81x	0.82x	0.75x	0.69x	0.89x	0.84x	0.75x

Celcuity Inc. (CELC) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare CELC vs Peers

vs RVMD

vs INCY

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Celcuity Inc. (CELC) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare CELC vs Peers

vs RVMD

vs INCY

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios